Follow-up to Nova: The Convert, the Capped Call, and What Capital Allocation Really Protected
Nova’s 2030 convert and capped-call package did not undo the dilution that had already reached common shareholders. They pushed the next dilution threshold much higher and bought protection only up to $415.03 per share, while the buyback offset only a small fraction of the shares already issued.
What This Follow-up Is Isolating
The main article already argued that Nova’s 2025 story is no longer only about growth. It is also about capital allocation. This follow-up isolates the more precise mechanism: what management actually achieved when it replaced an old convertible, whose dilution had already hit common holders, with a new 2030 convert, a capped-call package, and a buyback.
The central conclusion is straightforward: Nova did not erase dilution. It changed its shape. The old 2025 notes turned into 2,432,803 shares during 2025. The new 2030 notes push the next dilution layer up to an initial conversion price of about $320.16 per share, and the capped call buys protection only up to about $415.03. Inside that corridor, common shareholders get real protection. Outside it, or against the dilution that already happened, protection is partial or absent.
The second point: that protection cost real cash. In 2025 Nova paid $51.826 million for the capped call and another $1.407 million of related issuance costs. It also spent $35.003 million on repurchases. That means the shareholder-protection layer alone cost $88.236 million of cash, and the all-in amount rises to $107.787 million once the issuance costs of the new notes themselves are included.
The third point: the buyback was supportive, not reparative. In 2025 it retired 146,500 shares. That is less than 6.1% of the shares added in the same year through the conversion of the 2025 notes. Even if the full program since March 2022 is counted, only 560,001 shares have been retired, less than one quarter of the shares issued in 2025 from the old convert alone.
| Layer | What happened in 2025 | What it means for common holders |
|---|---|---|
| Dilution already realized | The 2025 notes converted into 2,432,803 shares and a de minimis $7 thousand cash payment | The dilution already entered the share count |
| New dilution layer | The 2030 notes were issued in a $750 million principal amount and convert at 3.1234 shares per $1,000, or roughly 2.343 million underlying shares | Future dilution moved to a much higher share price |
| Protection layer | The capped call carries the same strike reference and a $415.03 cap price | Protection exists only inside a defined corridor |
| Actual offset | 146,500 shares were repurchased in 2025 and 560,001 cumulatively since 2022 | That improves the margin, not the full dilution outcome |
The Dilution That Already Happened
To understand what Nova actually protected, the right place to start is the old convert. The 2025 notes carried a conversion price of about $74.60 per share. During 2025, $181.495 million of principal converted into 2,432,803 shares. The statement of changes in shareholders’ equity shows the effect clearly: shares outstanding rose from 29,278,401 at the end of 2024 to 31,780,111 at the end of 2025 even after repurchases.
That point is critical because it sets the correct reading order. The September 2025 financing was not designed to erase the share-count damage that had already been recognized. It was designed to manage the next dilution layer. Anyone looking only at the new convert and the capped call can miss that the larger protection package was put in place after common holders had already absorbed the main hit from the prior structure.
The numbers sharpen the point further. Even after spending $86.531 million on buybacks since 2022, the cumulative shares retired amount to only about 21.6% of the shares added in 2024 and 2025 through conversions of the old notes. That is why the repurchase program should not be read as a full anti-dilution solution. It is, at best, a partial defense of per-share economics.
The New Structure: Fewer Shares Per Dollar, Not Less Complexity
That brings the more important question: what did Nova actually gain with the 2030 notes. Here management deserves credit. The new convert was issued in a $750 million principal amount, 3.75 times the original size of the 2025 notes, but at a much lower share conversion rate: 3.1234 shares per $1,000 versus 13.4048 under the old notes. The new conversion price, about $320.16 per share, is 4.3 times the old conversion price of roughly $74.60.
That is the heart of the move. Nova raised much more capital, but pushed the next possible hit to common shareholders into a much higher share-price range. In share-equivalent terms, the new notes represent roughly 2.343 million underlying shares, almost the same order of magnitude as the 2.433 million shares already issued in 2025 from the old notes. So this is not a structure that makes conversion irrelevant. It is a structure that tries to move the conversion debate from a zone where conversion was already deeply in the money to a zone that requires a meaningfully higher stock price before dilution becomes live again.
There is a cost here too. At year-end 2025 the carrying value of the 2030 notes was $731.680 million after $18.320 million of unamortized issuance costs. But the estimated fair value already stood at about $936.270 million. That does not create an immediate cash outflow because the instrument is not marked through earnings. It does show that the market was already assigning substantial value to the conversion option that common shareholders had effectively granted to noteholders.
What the Capped Call Actually Bought
The capped call is the most sophisticated part of the structure, and also the part most likely to be overstated. Nova paid $51.826 million for it and another $1.407 million of related issuance costs. From an accounting perspective it was recorded as a reduction to equity, not as an asset remeasured every quarter. Economically, it is designed to reduce dilution or offset cash payments above principal if the stock rises above the strike built into the package.
But precision matters. The protection only really starts where the new problem starts. Its strike corresponds to the 2030 conversion price, about $320.16 per share. Its cap price is $415.03. In other words, Nova bought a protection corridor about 29.6% wide above the conversion price, not an open-ended insurance policy against any future share-price strength.
What does that mean in practice? As long as the stock remains below $320.16, the 2030 notes are not economically in the money and the new dilution layer stays dormant. Between $320.16 and $415.03, the capped call is expected to protect common shareholders or the company’s cash economics from a meaningful part of the damage. Above $415.03, that protection stops expanding. This does not make the move unattractive. On the contrary, it shows Nova was willing to spend real money to raise the dilution threshold and buy a sensible corridor of protection. It does mean that what was protected here is a specific band of future outcomes, not every upside scenario in the stock.
What the Buyback Actually Protected
The 2025 buyback amounted to $35.003 million for 146,500 shares, or an average price of about $238.93 per share. That is almost identical to the $237.16 reference share price used in the capped-call disclosure on September 2, 2025. The overlap helps explain management’s frame of reference: it was willing to deploy real cash around the same share-price neighborhood both to soften future dilution and to retire some stock directly.
Still, the outcome has to be read coldly. On a 2025-only basis, 146,500 repurchased shares versus 2,432,803 shares issued through the old convert means an offset of only a little over 6%. Even if the full program since 2022 is counted, 560,001 retired shares versus 2,432,803 shares issued in 2025 alone means only about a 23% offset. That is why the buyback mainly protected three things: the signal that management is willing to spend on common shareholders, a small part of per-share economics, and confidence around the new structure. It did not reset the clock.
That is the core of the story. Of the $750 million gross proceeds from the new convert, about 14.4% flowed back out immediately in the form of issuance costs, the hedging package, and repurchases. If only the capped call and buyback are counted, Nova allocated an amount equal to roughly 35.9% of 2025 operating cash flow to that shareholder-protection effort. If the note issuance costs are included as well, the all-in price rises to roughly 43.9% of operating cash flow. That is not a footnote. It is a heavy capital-allocation choice designed to improve common-shareholder economics, but not for free.
Conclusion
Nova’s 2025 move was rational, but it has to be read correctly. The company closed out an old dilution layer that had already turned into actual shares, raised a much larger amount through a new convert, and paid upfront to push the next future problem higher and buy a protection corridor. That improves common-shareholder economics across a broad success scenario, but it does not erase the price already paid along the way.
So the right question is not whether management “protected shareholders.” The right question is which shareholders, and at what stage. For the 2025 shareholder base, protection was only partial because the dilution from the old convert had already been realized. For future shareholders, Nova bought more meaningful protection, but only inside a defined price band and at a real cash cost.
From here the debate shifts to two questions. First, will Nova keep using cash to offset dilution, or will it prefer to direct that cash toward growth, acquisitions, and balance-sheet optionality. Second, will the stock actually spend meaningful time in the range where the capped call matters. If it does, the company will have proven that it bought real value for common holders. If it does not, part of that protection may look, in hindsight, like an expensive insurance policy on an upside scenario that never had to be paid.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.